Sign In
Buy BTMD
$2.11
-0.0400 (-1.86%)
At Close: Jun 03, 2026
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
08:00am, Monday, 01'st Jun 2026
IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026.
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
10:00am, Thursday, 28'th May 2026
[url="]Biote[/url] (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' pa
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
09:00am, Thursday, 28'th May 2026
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce
biote Corp. (BTMD) Q1 2026 Earnings Call Transcript
02:51am, Thursday, 07'th May 2026
biote Corp. (BTMD) Q1 2026 Earnings Call Transcript
biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates
07:35pm, Wednesday, 06'th May 2026
biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago.
Biote Reports First Quarter 2026 Financial Results
04:05pm, Wednesday, 06'th May 2026
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce
Biote Schedules First Quarter 2026 Financial Results Release and Conference Call
04:05pm, Wednesday, 22'nd Apr 2026
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of ou
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
11:52pm, Wednesday, 11'th Mar 2026
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
biote Corp. (BTMD) Q4 Earnings and Revenues Top Estimates
06:45pm, Wednesday, 11'th Mar 2026
biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.1 per share a year ago.
Biote Reports Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Wednesday, 11'th Mar 2026
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce
Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call
04:05pm, Wednesday, 25'th Feb 2026
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients' lives by providing hormone replacement therapy
Head to Head Comparison: Agilent Technologies (NYSE:A) vs. biote (NASDAQ:BTMD)
02:14am, Sunday, 07'th Dec 2025
biote (NASDAQ: BTMD - Get Free Report) and Agilent Technologies (NYSE: A - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on
biote Corp. $BTMD Stock Position Lessened by Bandera Partners LLC
03:36am, Tuesday, 25'th Nov 2025
Bandera Partners LLC decreased its position in shares of biote Corp. (NASDAQ: BTMD) by 6.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commiss
biote Corp. (BTMD) Q3 2025 Earnings Call Transcript
07:41pm, Wednesday, 05'th Nov 2025
biote Corp. ( BTMD ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Bret Christensen - CEO & Director Robert Peterson - CFO and Chief Business Officer Conference Call Particip
biote Corp. (BTMD) Tops Q3 Earnings and Revenue Estimates
07:16pm, Wednesday, 05'th Nov 2025
biote Corp. (BTMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.33 per share a year ago.
